Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...

Bioavailability Enhancement: Drug Permeability Enhancement

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Estimation of the concentration boundary layer adjacent to a flat surface using computational fluid dynamics.

International journal of pharmaceutics·2024

Same author

Particle Size, Dose, and Confinement Affect Passive Diffusion Flux through the Membrane Concentration Boundary Layer.

Molecular pharmaceutics·2023

Same author

Numerical simulation of peristalsis to study co-localization and intestinal distribution of a macromolecular drug and permeation enhancer.

International journal of biological macromolecules·2023

Same author

Effect of light source and UVA quotient on monoclonal antibody stability during ambient light exposure studies.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2023

Same author

Intrinsic lipolysis rate for systematic design of lipid-based formulations.

Drug delivery and translational research·2022

Same author

Ultrathin, Large-Area Membrane Diffusion Cell for pH-Dependent Simultaneous Dissolution and Absorption Studies.

Molecular pharmaceutics·2020

Search research articles

Related Experiment Video

Updated: May 17, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

Processing challenges with solid dosage formulations containing vitamin E TPGS.

Preetanshu Pandey¹, Patrick D Sinko, Dilbir S Bindra

¹Drug Product Science and Technology, Bristol-Myers Squibb, 1 Squibb Drive, New Brunswick, NJ 08901, USA. preetanshu.pandey@bms.com

Pharmaceutical Development and Technology

|November 10, 2012

Summary

Incorporating Vitamin E TPGS into solid dosage forms presents challenges. Adding Aeroperl 300 (colloidal silicon dioxide) to formulations significantly improves tablet compaction and quality during manufacturing.

More Related Videos

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

Related Experiment Videos

Last Updated: May 17, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

Area of Science:

Pharmaceutical Technology
Materials Science

Background:

Vitamin E TPGS (d-α tocopheryl polyethylene glycol 1000 succinate) is a common excipient in pharmaceutical formulations.
Incorporating lipophilic compounds like Vitamin E TPGS into solid dosage forms can pose processing challenges.

Purpose of the Study:

To investigate the processing challenges of incorporating Vitamin E TPGS into solid pharmaceutical dosage forms.
To evaluate methods for overcoming compaction issues associated with Vitamin E TPGS.

Main Methods:

Utilized wet granulation (high-shear and fluid bed) to incorporate Vitamin E TPGS into prototype formulations.
Assessed granulation properties and tablet compactability at various compression speeds.
Investigated the effect of intragranular Aeroperl 300 (colloidal silicon dioxide) on formulation properties.

Main Results:

Vitamin E TPGS could be incorporated at 10% w/w without initial processing issues.
Granulations exhibited poor compactability and tablet defects at high compression speeds (low dwell times).
Intragranular Aeroperl 300 addition improved granule characteristics (smaller size, higher porosity) and enhanced compactability.

Conclusions:

High concentrations of Vitamin E TPGS can negatively impact tablet compaction during high-speed manufacturing.
Aeroperl 300 effectively mitigates compaction issues, enabling successful processing of Vitamin E TPGS-containing formulations.
This finding is crucial for the development of stable and manufacturable solid dosage forms with Vitamin E TPGS.